NeoGenomics nets $30M in follow-on; Sensassure develops connected adult diaper;

@FierceMedDev: Blood test for drug-resistant malaria strain shows promise. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: ICYMI yesterday: Abbott gets $20M from DoD to develop portable concussion test. Article | Follow @StacyALawrence

@VarunSaxena2: My photo was published in @indystar! George Will: Progressives as economic innocents. Story via IndyStar | Follow @VarunSaxena2

@EmilyWFierce: Medtronic sticks to its guns on Covidien and reports strongest quarterly U.S. sales growth in 5 years. More from Reuters | Follow @EmilyWFierce

> Cancer diagnostics company NeoGenomics expects to net $30 million after discounts and expenses in a follow-on offering of 7 million shares at $4.60 each. More

> Sensassure is developing a diaper with a sensor for elderly citizens experiencing incontinence. The sensor will activate when a senior soils themselves and allow a member of the nursing staff to address the problem immediately, reducing the risk of subsequent health concerns. Story

> LeMaitre Vascular acquired Xenotis for $7.7 million. With the purchase, LeMaitre will add Xenotis' Omniflow II biological graft to its lineup. Read

Biotech News

@FierceBiotech: Amgen successfully hits another PhIII goal line with kidney dialysis drug. Story | Follow @FierceBiotech

@JohnCFierce: On again: Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal. Article | Follow @JohnCFierce

@DamianFierce: If Zosano Pharma pulls off its IPO this week, it'll be the 52nd biotech to go public this year, per . | Follow @DamianFierce

@EmilyMFierce: Over-hyped headline, but excellent points here: You Are Not Nearly Scared Enough About Ebola. More | Follow @EmilyMFierce

> Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal. Story

> Lilly grabs a 'tentative' FDA OK for insulin treatment, but Sanofi still blocks its path. More

> Dermira pockets $51M to bankroll skin treatments. News

> Amgen successfully hits another PhIII goal line with kidney dialysis drug. Article

Pharma News

@FiercePharma: Top-read on FP Monday: Should deal-needy Pfizer target antibiotics specialist Cubist? Article | Follow @FiercePharma

@TracyStaton: ICYMI yesterday: @NovoNordisk CEO on the house that Victoza built and the future of diabetes R&D. Report | Follow @TracyStaton

@EricPFierce: Indian drugmaker, Marck Biosciences, ravaged by FDA warning letter for records kept on 'scratch paper.' Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Reckitt Benckiser chief ahead of the consumer health curve, analysts say. Article | Follow @CarlyHFierce

> Merck seeking dismissal of Fosamax femur-fracture suits. Story

> Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion. Report

> Big investors urge drugmakers to stop badmouthing biosimilars. Article

Biotech Research News

> Bacteria injection shrinks tumors in animals. Report

> Diabetes culprit may be a single enzyme. Story

> Researchers unveil lung-on-a-chip device. Article

> Ebola protein discovery could aid drug development. More

> Organovo 3-D printed liver tissue moves closer to market. Item

Pharma Manufacturing News

> FDA warning letter says Marck plant plagued by faked records and dead frogs. Report

> Sweden's Recipharm moves on Italy with $160M deal for Corvette. More

> Big Pharma stands back as little guys work on plant-based drugs and manufacturing. Report

> Sun Pharma recalls nearly 500,000 bottles of antibiotics. Story

> Sanofi shipping new malaria treatment manufactured from 'semisynthetic artemisinin.' Article